- •Stabilizing organ-at-risk anatomy (OAR) is essential.
- •Interfraction prostate bed volume is stable despite deformable surrounding organs.
- •Target underdosing and OAR overdosing is avoided in post-prostatectomy radiotherapy.
- •Volumetric and dosimetric changes from rotation and intrafraction motion are minor.
- •Shape of prostate bed may also influence target coverage.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”).Urology. 2005; 66: 83-94
- Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).Lancet (London, England). 2012; 380: 2018-2027
- Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial.Eur Urol. 2014; 66: 243-250
- Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.J Urol. 2009; 181: 956-962
- Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer.J Clin Oncol. 2016; 34: 3864-3871
- Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension.Eur Urol. 2019;
- Fractionation and protraction for radiotherapy of prostate carcinoma.Int J Radiat Oncol Biol Phys. 1999; 43: 1095-1101
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.Lancet Oncol. 2016; 17: 1047-1060
- Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.J Clin Oncol. 2016; 34: 2325-2332
- Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer.J Clin Oncol. 2017; 35: 1884-1890
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.Lancet (London, England). 2019; 394: 385-395
- Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer.JAMA Network Open. 2019; 2e188006
- Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies.Int J Radiat Oncol Biol Phys. 2019; 104: 778-789
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.Lancet Oncol. 2019;
- Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.Int J Radiat Oncol Biol Phys. 2014; 90: 926-933
- Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2016; 94: 605-611
- Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity.Clin Genitourinary Cancer. 2017; 15: e667-e673
- Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.Cancer. 2011; 117: 2629-2636
- Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome.Cancer Manag Res. 2018; 10: 473-480
- Prostate bed stereotactic body radiation therapy (PB-SBRT) for postprostatectomy biochemical recurrence: first toxicity results of a phase 1 dose-escalation trial.Int J Radiat Oncol Biol Phys. 2016; 96: E227-E228
- Phase I study of stereotactic body radiotherapy following radical prostatectomy.J Clin Oncol. 2018; 36 (TPS158–TPS158)
- Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy.Radiother Oncol. 2013; 107: 165-170
- Conventional margins not sufficient for post-prostatectomy prostate bed coverage: an analysis of 477 cone-beam computed tomography scans.Radiother Oncol. 2014; 110: 235-239
- The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy.Radiother Oncol. 2014; 110: 245-250
- Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy.Int J Radiat Oncol Biol Phys. 2013; 85: 1038-1044
- Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2010; 76: 361-368
- Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy.Int J Radiat Oncol Biol Phys. 2011; 79: 188-194
- Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy.Med Phys. 2014; 41031710
- Which bowel preparation is best? Comparison of a high-fibre diet leaflet, daily microenema and no preparation in prostate cancer patients treated with radical radiotherapy to assess the effect on planned target volume shifts due to rectal distension.Br J Radiol. 2013; 86 (20130457–20130457)
- Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.Int J Radiat Oncol Biol Phys. 2011; 79: 623-632